HOW TO DESIGN A STUDY Nikolaos P. Polyzos M.D. PhD The material was supported by an educational grant from Ferring Type of Study and Level of Evidence RCTs Meta-analyses of RCTs LEVEL I Cohorts, case control studies, crosssectional surveys Case series, case reports, guidelines, expert opinions LEVEL II LEVEL III What type of study should I perform? It depends on what you are seeking General Types of Studies • Observational: – Searching for association or relationship • Interventional: (clinical trials) – Validating a specific treatment protocol Observational Studies • Cross-sectional studies • Case-control studies • Cohort studies Cross-sectional study Cross-sectional surveys A “photograph” of the population at a specific moment Aim • Assess the prevalence of acute or chronic conditions • Check association between characteristics of the population Example of cross-sectional study Association of blood type and patient characteristics with ovarian reserve. • Determination of blood type • Determination of FSH levels Timberlake KS et al., Fertil Steril. 2013 Case-control study Case-control studies (1) Cases (patients with a disease) Controls (patients without the disease) Advantages: • Case-control studies are simple to organise • Retrospectively compare two groups • Aim to identify predictors of an outcome Case control studies (2) Exposure CASES (present) (?) CONTROLS (absent) e.g. BMI e.g. Endometriosis Investigator (?) Disease Deep infiltrating endometriosis is associated with markedly lower body mass index: a 476 casecontrol study. • Cases- endometriosis • Controls- no endometriosis • Check for difference in BMI Cohort study Cohort studies • Follow a specific cohort • A cohort is a group of people who share a common characteristic or experience within a defined period Advantage: Can examine causal relationship and predictive ability of a marker Cohort studies- retrospective Exposure (?) NO (?) e.g. AMH values e.g. Pregnancy outcome Investigator YES Disease-outcome Examples of a retrospective cohort Predictors of ovarian response in women treated with corifollitropin alfa for IVF/ICSI. Polyzos et al., Fertil Steril 2013 Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. Polyzos et al., RBMonline 2013 • Retrospectively examined patients files • Recorded AMH values • Checked who were the patients pregnant and not pregnant Cohort studies- prospective Disease-outcome Exposure NO e.g. AMH values Investigator YES (?) (?) e.g. Pregnancy outcome Example of a prospective cohort The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. Mahran et al., JCEM 2013 • • • Prospectively enrolled patients before treatment begins Recorded AMH values Waited till the cycles finished to evaluate how many responded Clinical trials Types of Clinical Trials • Randomized versus non-randomized • Treatment arm -- with or without a control arm • Testing the safety and effectiveness of a drug or intervention Clinical Trials: Phases I - IV • Phase I – Safety-testing small groups of 10 to 15 patients • Phase II – Pilot studies to confirm effectiveness of the drug - less than 100 patients Clinical Trials: Phases I - IV • Phase III – Large groups of patients for statistical confirmation of effect and incidence of side-effects > 100 patients • Phase IV – Post marketing studies - fine tuning, and new rare findings from a very large population Randomized Clinical Trials LEVEL I Evidence Randomized Controlled Studies Description: • After assessment of eligibility and recruitment, but before the intervention to be studied begins, randomly allocated to receive one or other of the alternative treatments under study Randomized Controlled Studies Advantage: • RCTs are considered by most to be the most reliable form of scientific evidence in the hierarchy of evidence that influences healthcare policy and practice Randomized Controlled Studies Disadvantages: • Costs • Time • Rare events Designing a clinical and especially a randomized trial … … Is it that easy? It can be... The Study Protocol ...possibly the most important part of your trial Proper Study Protocol • • • • Research question--rationale Exact study design Inclusion-exclusion criteria Randomization procedure, allocation concealment, blinding • Timing of blood sampling and monitoring • Clearly defined interventions Proper Study Protocol • • • • • Primary outcomes Appropriate statistical analysis Feasibility of the study Data management Ethical considerations Research Question and Hypothesis • Simple – one question and one answer • In accordance with the available evidence • Ask yourself: – Why is such a study valuable? – Can it change clinical practice? Study Design • Parallel group – Each participant is randomly assigned to a group, and all participants receive (or not), an intervention. • Crossover – Over time, each participant receives (or not), an intervention in a random sequence. Study Design • Cluster – Pre-existing groups of participants, (e.g. villages, schools) are randomly selected to receive, or not to receive, an intervention Study Design (3) • Factorial – Each participant is randomly assigned to a group that receives a particular combination of interventions or non-interventions – (e.g., group 1 receives vitamin X and vitamin Y, group 2 receives vitamin X and placebo Y, group 3 receives placebo X and vitamin Y, and group 4 receives placebo X and placebo Y) Population to Include.. • • • • Clearly defined Easy to recruit Easy to follow Sample presumed to represent population Unclear Population… Not Replicable Results • 47 randomized trials using 41 definitions for poor ovarian responders • No more than 3 trials used the same definition • Even trials from the same research group used a different definition Who are the poor ovarian responders? Randomization Procedure (1) • Simple randomization • Block randomization • Computer generated list Randomization Procedure (2) Generation of allocation sequences • Adequate if sequences are suitable to prevent selection bias: random numbers generated by computer, table of random numbers, drawing of lots or envelopes, tossing a coin, shuffling cards, throwing dice, etc. • Inadequate if sequences could be related to prognosis and thus introduce selection bias: case of record number; date of birth; day, month, or year of admission; etc. Juni P et al., BMJ 2001 Randomization and Concealment of Patient Allocation • The procedure for protecting the randomization process so that the treatment to be allocated is not known before patient is entered into the study • Methods to ensure – sequentially numbered, opaque, sealed envelopes (SNOSE) – sequentially numbered containers – pharmacy controlled randomization – central randomization Juni P et al., BMJ 2001 Randomization and Concealment of Patient Allocation (continued) Generation of allocation sequences • Adequate if sequences are suitable to prevent selection bias: random numbers generated by computer, table of random numbers, drawing of lots or envelopes, tossing a coin, shuffling cards, throwing dice, etc. • Inadequate if sequences could be related to prognosis and thus introduce selection bias: case of record number; date of birth; day, month, or year of admission; etc. Juni P et al., BMJ 2001 Randomization and Concealment of Patient Allocation (continued) Generation of allocation sequences (cont): • Inadequate if patients and investigators enrolling patients can foresee assignments and thus introduce selection bias: procedures based on inadequate generation of allocation sequences, open allocation schedule, alternation and other unsealed or non-opaque envelopes, etc. Juni P et al., BMJ 2001 Randomization and “Blinding” Status of Subjects • Procedures that prevent study participants, caregivers, or outcome assessors from knowing (by randomization) which intervention was received • Types – Single-blind – Double-blind – Open Label Strength of Randomization • Inadequate if patients and investigators enrolling patients can foresee assignments and thus introduce selection bias: procedures based on inadequate generation of allocation sequences, open allocation schedule, alternation and other unsealed or non-opaque envelopes, etc. Juni P et al., BMJ 2001 Monitoring Patients First Consultation Assessment Clinical examination: Vital signs and Weight Pregnancy Test Laboratory exams (local lab): - Chemistry/ Hematology - FSH, LH, E2, P - AMH USS ART Procedures Previous and Concomitant Medication (S)AEs Cycle Summary Subject Status Stimulation Day 1 2 3 4 6 7 8 10 Day of hCG OPU ET OPU + 14 Days ET + 35-42 Days ET + 4956 Days Cycle Disco n X X X X X X X X X X X X X X X X X X X X X X Whenever previous or concomitant mediation is used Whenever an (S)AE occurs At cycle discontinuation or completion At trial discontinuation or completion X Clearly defining interventions ADMINISTRATION DAY MEDICATION 1 2 3 4 5 6 7 8 10 X X X X X X X X X X X X X X X X X Investigational Group Drug A Drug B X X X X Reference Group Drug C Drug D X X X X X Both Groups Drug E X Choosing Primary Outcomes • Select a primary • Exact timing when the primary outcome is measured • Secondary outcomes may also be selected • Do not select surrogate outcomes, e.g., pregnancy – not oocytes, nor embryos Juni P et al., BMJ 2001 Calculating Sample Sizes • Power: What sample size needed? Calculation will be based on: – Expected 80% power, level of significance P< 0.05 – Estimated sample recruitment based on previous evidence. – Do not make your sample size based on unrealistic assumptions. • During the protocol formulation describe the statistics to be used. Performing Statistical Analysis Who is going to be the “person behind your numbers”? • Crucial part of any clinical trial – Wrong analysis = wrong results – Improper test = not valid study – A statistical mistake can jeopardize years of work Determine Feasibility of Conducting the Study • Are resources available (funding, personnel)? • Can an adequate number of patients be recruited? • Will it be easy to follow your patients (subjects)? Data Management Case report forms (CRF) Uniform templates for extracting data Ethical Considerations • Institutional Review Board (IRB) • ERB approval (Ethical Review Board) • Inform consents • Trial registration • Sponsorship Acknowledgement 11. Ethical considerations • • • • • IRB approval Inform consents Acceptance from National competent authorities Trial registration Sponsorship Institutional Review Board (IRB) Approval • All institutions should have (by law or regulation) an IRB to evaluate whether it’s ethical to conduct a given study • Submit your protocol and wait for acceptance prior conducting a trial • Follow institutional instructions and explain in detail the rationale, population, interventions, and goals of the study Inform Your Patients Properly…. Obtain Their Written Consent….. • Very detailed information for the treatment (drugs, duration, procedures) • Current gold standard • Expectation that the new treatment may show a difference • Avoid scientific terms … let them understand (6th - 8th grade level) • List potential side effects and who takes responsibility • Obtain their signature, usually requiring a witness Acceptance from National competent authorities • Regulatory authorities responsible for human medicines • Only for medicines or devices • It is ILLEGAL to perform a trial with a medicinal product without having acceptance from your National competent authority Register Your Trial ! • After approval of relevant IRB, register your trial in a trial registry - (e.g. clinicaltrials.gov) • For publication, most journals require trial registration prior the conduction of the study Declare Any Indirect or Direct Funding From the Industry • ICJME suggests reporting any potential conflict(s) of interest related (or not related) to the study, err on the conservative side • Industry funding should be reported Institutional Review Board (IRB) approval • All institutions should have (by law) an IRB to evaluate whether it is ethical to conduct the study • Submit your protocol and wait for acceptance prior to conducting a trial • Explain in detail the rationale, the population, the interventions and the goals of the study Inform your patients properly…. Get their written consent….. • Very detailed information for the treatment (drugs, duration, procedures) • What is the current gold standard • Why do you expect the new treatment to show difference • Do not use scientific terms…let them understand • Inform about potential side-effects and who is taking any liability in such a case • Obtain their signature Register your trial in a public trial registry (1) • After approval of IRB register your trial in a trial registry • Most journals require trial registration prior to the conduction of the study Register your trial in a public trial registry (2) AVAILABLE REGISTRIES FOR CLINICAL TRIALS • Australia and New Zealand's (ANZCTR) (http://www.anzctr.org.au) • Brazilian Clinical Trials Registry (ReBec) (http://www.ensaiosclinicos.gov.br) • Chinese Clinical Trial Registry (ChiCTR) (http://www.chictr.org) • Clinical Research Information Service (CRiS), Republic of Korea (http://cris.cdc.go.kr) • Clinical Trials Registry - India (CTRI) (http://ctri.nic.in) • Cuban Public Registry of Clinical Trials(RPCEC) (http://registroclinico.sld.cu) • EU Clinical Trials Register (EU-CTR) (https://www.clinicaltrialsregister.eu/) Register your trial in a public trial registry (3) AVAILABLE REGISTRIES FOR CLINICAL TRIALS • • • • • • • German Clinical Trials Register (DRKS) (http://www.drks.de) Iranian Registry of Clinical Trials (IRCT) (http://www.irct.ir/) Japan's UMIN-CTR (http://umin.ac.jp) The Netherlands, Trialregister.nl The United States, ClinicalTrials.gov The International, ISRCTN.org Pan African Clinical Trial Registry (PACTR) (http://www.pactr.org/) Declare any indirect or direct funding from industry • ICJME suggests reporting of any potential conflict of interest related or not to the study • Industry funding should be reported Randomized Clinical Trials Thank you